What is she best known for?
The fields of study she is best known for:
- Cancer
- Gene
- Internal medicine
Sabine Tejpar focuses on Colorectal cancer, Internal medicine, Oncology, KRAS and Cetuximab.
Her Colorectal cancer research includes themes of Cancer research, Microsatellite instability and Bioinformatics.
Within one scientific family, Sabine Tejpar focuses on topics pertaining to Endocrinology under Internal medicine, and may sometimes address concerns connected to Combination chemotherapy and Gastroenterology.
Her Oncology study combines topics from a wide range of disciplines, such as Epiregulin, Proportional hazards model, Hazard ratio, Bevacizumab and Primary tumor.
The study incorporates disciplines such as Exon, Lung cancer, Pathology and Survival analysis in addition to KRAS.
Sabine Tejpar interconnects Neuroblastoma RAS viral oncogene homolog and Monoclonal in the investigation of issues within Cetuximab.
Her most cited work include:
- Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. (2984 citations)
- The consensus molecular subtypes of colorectal cancer (1870 citations)
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis (1560 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Colorectal cancer, Internal medicine, Oncology, Cancer research and KRAS.
Cetuximab is the focus of her Colorectal cancer research.
Internal medicine is often connected to Surgery in her work.
Her Oncology research is multidisciplinary, relying on both Biomarker, Proportional hazards model, Hazard ratio, Bevacizumab and Panitumumab.
Her Cancer research research is multidisciplinary, incorporating perspectives in Cell, Wnt signaling pathway, Gene, Cancer cell and PI3K/AKT/mTOR pathway.
Her KRAS research includes themes of Survival analysis, Growth factor receptor, Mutant and Gene expression.
She most often published in these fields:
- Colorectal cancer (63.17%)
- Internal medicine (48.80%)
- Oncology (43.71%)
What were the highlights of her more recent work (between 2016-2021)?
- Colorectal cancer (63.17%)
- Internal medicine (48.80%)
- Oncology (43.71%)
In recent papers she was focusing on the following fields of study:
Her main research concerns Colorectal cancer, Internal medicine, Oncology, Cancer research and KRAS.
Her research on Colorectal cancer focuses in particular on Cetuximab.
She has included themes like Epidermal growth factor and Surgery in her Cetuximab study.
When carried out as part of a general Internal medicine research project, her work on FOLFIRI, Irinotecan, Biomarker and Disease is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
The study incorporates disciplines such as Cancer, Clinical trial, Proportional hazards model, Hazard ratio and Bevacizumab in addition to Oncology.
Her Cancer research research incorporates elements of Cancer cell, Cell, Gene and Immunotherapy.
Between 2016 and 2021, her most popular works were:
- Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer (375 citations)
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (346 citations)
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. (140 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Sabine Tejpar mainly investigates Colorectal cancer, Internal medicine, Oncology, Cancer research and Immunotherapy.
Her study in Cetuximab and KRAS is carried out as part of her studies in Colorectal cancer.
In her study, which falls under the umbrella issue of KRAS, Surgery is strongly linked to First line.
She works mostly in the field of Internal medicine, limiting it down to topics relating to Gastroenterology and, in certain cases, Crossover study, Lynch syndrome, Adenoma and Relative risk.
Her work carried out in the field of Oncology brings together such families of science as Precision medicine, FOLFIRI, Proportional hazards model, Hazard ratio and Bevacizumab.
Her research integrates issues of Cancer cell, Regulation of gene expression and Gene expression profiling in her study of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
